Latest Breaking News On - Patients undergoing on pump cardiac - Page 1 : comparemela.com

UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

TORONTO, April 02, 2024 Arch Biopartners Inc., , announced today that three additional clinical sites in Turkey have joined the Phase II trial for LSALT peptide targeting the prevention and.

Arch Biopartners Adds Three New Clinical Sites into the

TORONTO, April 02, 2024 (GLOBE NEWSWIRE) Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that.

Arch Biopartners Receives Health Canada Approval to Conduct

TORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it.

Arch Biopartners Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury